The Promise and Challenges of Cell Therapy for Psoriasis
Studysummary In this review, the authors discuss the potential for cell therapy, such as hematopoietic stem cell transplantation and mesenchymal stromal cells, to treat severe psoriasis unresponsive to biological therapies, while highlighting the associated risks, costs, and regulatory challenges. Our plain-language summary of this paper — not a Tressless recommendation.
The review article discusses the potential and challenges of using cell therapy for treating severe psoriasis, especially in patients unresponsive to biologic therapies. Mesenchymal stem cells (MSCs) and haematopoietic stem cell transplantation (HSCT) offer immunomodulatory and anti-inflammatory benefits, but come with significant risks, costs, and regulatory challenges. MSCs and T regulatory cells (Tregs) are highlighted as potentially safer options compared to HSCT. The article emphasizes the need for well-designed, controlled trials to evaluate the efficacy and safety of these therapies. Early trials show promise, but larger studies are necessary to confirm their effectiveness and address clinical application challenges.
